Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:ONC)

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

PR Newswire 9 days ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

PR Newswire 10 days ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

PR Newswire October 4, 2024

Oncolytics Biotech reports positive results from breast cancer study

Jocelyn Aspa September 19, 2024

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

PR Newswire September 19, 2024

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

PR Newswire September 6, 2024

Sernova Corp. Announces Appointment of New Chief Executive Officer

GlobeNewswire August 12, 2024

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

PR Newswire August 2, 2024

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

PR Newswire August 1, 2024
View More News ››

Opinion & Analysis (TSX:ONC)

Buzz on the Bullboards: New Year, New Attractive Stocks

Omri Wallach January 9, 2020

Target Price Raised Ninefold on Biotech After Share Consolidation

Streetwise Reports June 6, 2018

Canadian Biotech comes back to life: A buyer's guide

Tony Pullen January 21, 2014
View More Opinion ››

Bullboard Posts (TSX:ONC)

RE:new article

Try this link: :''https://healthandpharma.net/oncolife/5''. It is on page 26 to 29.
Hydro1 - 6 hours ago

RE:RE:RE:RE:My thanks , philosophical thoughts

Using an adaptive model of trial design, starting a Phase 2 trial and then getting an Accelerated Approval has the Phase 2 trial...
Noteable - 9 hours ago

new article

How Oncolytic Viruses Could Be a New Frontier in Transforming Cancer Treatment
spesestsemper - 11 hours ago

RE:RE:RE:My thanks , philosophical thoughts

well, yes, accelerated approval would be excellent... pray tell how that can happen without data ?? the HAVE to run another Phase II...
Quentin30 - 12 hours ago

RE:RE:How does Accelerated Approval work

Phase 2 Ziihera is approved under the FDA’s accelerated pathway. To keep it on the market, Jazz and Zymeworks are running the Phase III...
Noteable - 18 hours ago

RE:How does Accelerated Approval work

November 21, 2024 - Vancouver BC. -  FDA grants Zymeworks Inc its.Phase 2 HER2+ bispecifc antibody zanidatamab (Ziihera...
Noteable - 18 hours ago
View more Bullboard ››

SKRR Exploration Inc.

SKRR Exploration Inc.

SKRR Exploration Inc. is a Canada-based precious and base metal explorer with properties in Saskatchewan. The Company's ...
View More »